Highlights

07-06 Laboratorio Erfo continues buyback, acquires 15,000 treasury shares AN
06-29 Laboratorio Farmaceutico Erfo buys back 14,000 treasury shares AN
06-22 Erfo Keeps Buying Back Stock, Repurchases 28,000 Shares AN
06-20 Laboratorio Farmaceutico Erfo S.p.A.'s Equity Buyback announced on December 18, 2024, has expired. CI
06-15 Laboratorio Farmaceutico Erfo acquires 15,000 treasury shares AN
05-21 Laboratorio Farmaceutico Erfo reports stable first-quarter revenue year-on-year AN
05-21 Laboratorio Farmaceutico Erfo Q1 EBITDA adj. EUR 0.5 mln RE
04-13 Laboratorio Farmaceutico Erfo S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
03-30 Laboratorio Farmaceutico Erfo posts triple-digit profit growth in 2025 AN
02-19 Erfo Increases EBITDA in 2025; Revenues More Than Double AN
02-19 Laboratorio Farmaceutico Erfo FY EBITDA EUR 2.0 Mln RE
11-21 Erfo Pharmaceutical Laboratory, revenues grow by 57% in nine months AN
11-21 Laboratorio Farmaceutico Erfo 9m Ebitda EUR 1.7 mln RE
29/09/25 Erfo Pharmaceutical Laboratory improves profits in the first half AN
29/09/25 Erfo H1 EBITDA EUR 1.2 mln RE
27/09/25 Laboratorio Farmaceutico Erfo S.p.A. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
28/08/25 Laboratorio Erfo Reports Double-Digit Growth in Revenue and EBITDA for First Half AN
28/08/25 Laboratorio Farmaceutico Erfo H1 ebitda eur 1.2 mln RE
14/07/25 Laboratorio Farmaceutico Erfo Purchases 13,000 Own Ordinary Shares AN
23/05/25 Laboratorio Erfo, revenues and EBITDA up significantly in the quarter AN
23/05/25 Erfo Q1 EBITDA EUR 0.5 Mln RE
21/05/25 Erfo presents Osteo-therapy, a nutraceutical supplement AN
01/04/25 Laboratorio Farmaceutico Erfo FY EBITDA Adj EUR 1.4 MlN RE
31/03/25 Laboratorio Farmaceutico Erfo S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
20/02/25 Erfo Pharmaceutical Laboratory, revenues stable in 2024; Ebitda drops AN
No results match your criteria